富祥药业(300497) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥294,461,087.88, a decrease of 31.65% compared to the same period last year[1]. - The net profit attributable to shareholders was -¥39,615,709.98, representing an 80.38% decline year-over-year[1]. - Total operating revenue for the third quarter was ¥976,875,468.35, a decrease of 24.0% compared to ¥1,286,439,179.08 in the same period last year[21]. - Gross profit was negative at -¥100,656,281.91, compared to -¥78,024,580.37 in the previous year, indicating a worsening financial performance[22]. - Net profit for the period was -¥69,207,486.70, an improvement from -¥92,909,101.51 in the same quarter last year, reflecting a reduction in losses[23]. - Basic and diluted earnings per share were both -¥0.12, compared to -¥0.15 in the previous year[23]. - The company reported a financial expense of ¥22,690,659.57, which increased from ¥15,688,898.14 in the previous year[22]. Cash Flow - The net cash flow from operating activities increased significantly to ¥150,356,469.13, a rise of 1007.39% compared to the previous year[4]. - Operating cash inflow for the third quarter was CNY 864,365,162.52, a slight decrease from CNY 876,012,808.90 in the previous year[25]. - Net cash flow from operating activities was CNY 150,356,469.13, a significant improvement compared to a net outflow of CNY -16,570,141.01 in the same period last year[25]. - Cash outflow from investing activities totaled CNY 133,328,359.57, down from CNY 395,844,316.86 year-over-year[25]. - Net cash flow from financing activities was CNY -13,254,933.01, contrasting with a positive flow of CNY 155,395,309.53 in the previous year[25]. - The company reported a net increase in cash and cash equivalents of CNY 9,081,653.94, compared to a decrease of CNY -205,856,935.09 in the same quarter last year[25]. - The ending balance of cash and cash equivalents was CNY 589,836,920.62, down from CNY 641,395,653.15 year-over-year[25]. - The company received tax refunds amounting to CNY 115,330,033.75, significantly higher than CNY 43,240,624.56 in the previous year[25]. - Cash paid to employees was CNY 143,634,470.30, a decrease from CNY 162,553,837.42 in the same quarter last year[25]. - Cash outflow for purchasing goods and services was CNY 475,393,887.59, down from CNY 609,441,690.00 year-over-year[25]. Assets and Liabilities - Total assets as of September 30, 2024, were ¥4,649,243,003.01, down 3.52% from the end of the previous year[1]. - The company's equity attributable to shareholders decreased by 3.83% to ¥2,389,587,297.18 compared to the end of the previous year[1]. - The total liabilities decreased to ¥2,261,972,957.91 from ¥2,348,298,828.04, a reduction of approximately 3.7%[22]. - Current assets totaled 1.684 billion yuan, down from 1.877 billion yuan at the beginning of the period[19]. - The company’s fixed assets were valued at 1.528 billion yuan, a decrease from 1.635 billion yuan at the beginning of the period[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,857, with the largest shareholder, Bao Jianhua, holding 19.71% of shares, equating to 108,399,908 shares[6]. - The company repurchased a total of 11,355,900 shares, representing 2.06% of the total share capital[7]. - Bao Jianhua's pledged shares amount to 33,530,000, with a total of 81,299,931 shares under lock-up conditions[9]. - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Yu Wenjun, owning 3.20% or 17,621,846 shares[6]. - The company has released 10,979,962 shares from lock-up conditions during the reporting period, reducing the total locked shares to 98,384,106[10]. - The total number of shares held by the top ten unrestricted shareholders is 27,099,977, with Bao Jianhua being the largest holder[6]. - The company has a total of 86,111,856 restricted shares at the beginning of the period, with 6,574,500 shares released during the period[9]. - The total number of shares held by Yu Wenjun decreased to 13,216,384 after the release of 4,405,462 shares from lock-up[10]. - The company has a diverse shareholder base, including domestic individuals and institutional investors, with significant stakes held by various funds[6]. Business Development - The company obtained two national invention patents, which are expected to enhance product competitiveness and drive long-term business growth[12]. - A cooperation agreement was signed with Jiangxi Normal University to innovate the production process of key pharmaceutical intermediates, aiming to reduce production costs by 15%-20%[13]. - The company acquired a 30% stake in Aotong Pharmaceutical, with an assessed value of 60.0811 million yuan, enhancing control over subsidiaries[14]. - The company was recognized as a national-level "specialized, refined, and innovative" small giant enterprise, which is expected to improve brand image and core competitiveness[16]. - The subsidiary Xiangtai Science has successfully initiated trial production of a key raw material for antibiotics, with steady improvements in yield and equipment performance[17]. Research and Development - Research and development expenses decreased to ¥54,877,753.79, down 13.6% from ¥63,502,264.13 year-over-year[22]. Audit Status - The company has not undergone an audit for the third quarter report[26].